{
    "nctId": "NCT03775928",
    "briefTitle": "Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer",
    "officialTitle": "Phase \u2161 Study of Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Triple-negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 80,
    "primaryOutcomeMeasure": "progression-free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age\uff1a18\\~75 years;\n2. Triple-negative breast cancer (TNBC) confirmed by histology examination;\n3. patients had received first-line combination chemotherapy for advanced metastatic disease, and had a complete response, partial response or stable disease according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria;\n4. received endocrine therapy for metastatic disease before first-line chemotherapy were allowed;\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n6. A life expectancy of more than 12 weeks;\n7. Baseline blood routine examination in accordance with the following criteria : ANC\u22651.5\u00d7109/L\uff0cPLT\u226590\u00d7109/L\uff0cHb\u226590g/L;\n8. Liver and renal function in accordance with the following criteria: total bilirubin less than 1.5 times the upper limit of normal value; aspartate aminotransferase (AST), or alanine aminotransferase (ALT) less than 2.5 times the upper limit of normal value, less than 5 times the upper limit of normal value in patients with liver metastases.\n\n   the creatinine clearance rate calculated greater than 60 mL/min;\n9. Females of childbearing potential must be a pregnancy test in 7 days before participating ( including serum or urine), and the results were negative, and they are willing to take effective contraceptive methods During the trial and within 8 weeks after the last dose;\n10. Obtain informed consent from patients before starting any research-related operations and treatments to confirm that patients are willing to participate in this study and comply with research-related requirements.\n\nExclusion Criteria:\n\n1. Metastasis/recurrence occurs within 6 months of adjuvant chemotherapy;\n2. controlled high blood pressure, systolic blood pressure \u2265150mmHg or diastolic blood pressure \u2265100mmHg;\n3. urine routine test with urinary protein more than ++, or 24 hour urinary protein more than 1.0 g;\n4. abnormal coagulation function (INR \\> 1.5 or prothrombin time (PT) \\> ULN+4 seconds or APTT \\>1.5 times the ULN);\n5. Pregnant or lactating woman;\n6. Symptomatic brain parenchymal and/or pia mater metastases without treatment and control;\n7. Patients with Other malignant tumors in the past 5 years, except for fully treated cervical carcinoma in situ, cutaneous squamous cell carcinoma or well-controlled localized basal cell skin cancer;\n8. Mental illness or other condition that affects patient compliance;\n9. serious and uncontrollable systemic diseases (eg clinically significant cardiovascular disease, lung or metabolic disease, arteriovenous thrombosis, etc.) happened recently;\n10. Can not take or absorb oral drugs;\n11. Receiving any other testing drugs, or participating in other clinical trial 30 days before being enrolled in this trial;\n12. The patient has previously received treatment with an anti-angiogenic drug (whether adjuvant or palliative);\n13. Known or suspected to be allergic to any research drug or excipient;\n14. Any other researcher believes that it is not appropriate to participate in this test.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}